Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial

Practice Gap

Appropriate selection of kidney transplant patients in whom early conversion from either tacrolimus or cyclosporine to everolimus in a CNI-free regimen would be advantageous, based on an understanding of the balance between potential benefits and potential risks.

Learner Objectives
As a result of participating in this activity, participants will be able to:
1. Evaluate how kidney graft function is likely to progress after early conversion of kidney transplant patients to everolimus from tacrolimus or cyclosporine.
2. Assess the risk for biopsy-proven acute rejection in the same setting.
3. Understand whether there is likely to be a long-term impact of conversion in terms of cardioprotective effects, development of donor specific antibodies and viral infections.

Accreditation
The American Society of Transplant Surgeons (ASTS) is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
ASTS designates this enduring material activity for a maximum of 1.0 AMA
PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Activity Disclosures
None of the authors, planners, staff or CME committee members for this activity had any relevant financial relationships with commercial interests to disclose.

Instructions for completing ASTS MOC – Education through AJT modules

1. Review article.
2. Complete post-test. A passing score of 75% is required to move forward. The test can be retaken as many times as necessary.
3. Complete the evaluation.
4. Access your AJT MOC certificate(s) and transcript of modules completed under the “My Learning” tab.